Rationale, Opportunities, and Reality of Biosimilar Medications REPLY
Publication
, Journal Article
Lyman, GH; Zon, R; Harvey, RD
Published in: NEW ENGLAND JOURNAL OF MEDICINE
2018
Duke Scholars
Published In
NEW ENGLAND JOURNAL OF MEDICINE
EISSN
1533-4406
ISSN
0028-4793
Publication Date
2018
Volume
379
Issue
7
Start / End Page
694 / 695
Related Subject Headings
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., Zon, R., & Harvey, R. D. (2018). Rationale, Opportunities, and Reality of Biosimilar Medications REPLY. NEW ENGLAND JOURNAL OF MEDICINE, 379(7), 694–695.
Lyman, Gary H., Robin Zon, and R Donald Harvey. “Rationale, Opportunities, and Reality of Biosimilar Medications REPLY.” NEW ENGLAND JOURNAL OF MEDICINE 379, no. 7 (2018): 694–95.
Lyman GH, Zon R, Harvey RD. Rationale, Opportunities, and Reality of Biosimilar Medications REPLY. NEW ENGLAND JOURNAL OF MEDICINE. 2018;379(7):694–5.
Lyman, Gary H., et al. “Rationale, Opportunities, and Reality of Biosimilar Medications REPLY.” NEW ENGLAND JOURNAL OF MEDICINE, vol. 379, no. 7, 2018, pp. 694–95.
Lyman GH, Zon R, Harvey RD. Rationale, Opportunities, and Reality of Biosimilar Medications REPLY. NEW ENGLAND JOURNAL OF MEDICINE. 2018;379(7):694–695.
Published In
NEW ENGLAND JOURNAL OF MEDICINE
EISSN
1533-4406
ISSN
0028-4793
Publication Date
2018
Volume
379
Issue
7
Start / End Page
694 / 695
Related Subject Headings
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences